Bucek Robert A, Puchner Stefan, Lammer Johannes
Department of Angiography and Interventional Radiology, Vienna Medical University, Waehringer Guertel 18-20, 1090 Vienna, Austria.
AJR Am J Roentgenol. 2006 Mar;186(3):877-82. doi: 10.2214/AJR.04.1767.
Our objective was to assess the mid- and long-term outcomes concerning fibroid-specific and fibroid-associated quality of life in patients treated by uterine fibroid embolization.
A retrospective cohort study was performed, including consecutive patients with a minimum follow-up of 1 year. Analysis was performed by a questionnaire consisting of 49 questions about six topics: baseline characteristics, preinterventional status, diagnostic workup and treatment planning, periinterventional period and procedure-related quality of life, follow-up, and general satisfaction.
The analysis was performed based on questionnaires from 53 (85.5%) of 62 patients. The mean follow-up was 3.0 +/- 1.0 (SD) years (range, 1.0-5.0 years). Uterine fibroid embolization led to a reduction of bleeding symptoms in 79.2% of patients (n = 48 before uterine fibroid embolization; n = 10 after uterine fibroid embolization), pain in 81.5% (n = 27; n = five, respectively), bulk-related symptoms in 78.6% (n = 14; n = three, respectively), urinary dysfunction in 60% (n = 10; n = four, respectively), sexual dysfunction in 71.4% (n = seven; n = two, respectively), fatigue in 62.5% (n = 24; n = nine, respectively), limitations in social life in 88.2% (n = 17; n = two, respectively), and a depressed mood in 89.5% (n = 19; n = two, respectively). The median impairment score for bleeding and pain decreased significantly from 6 to 0 and from 4 to 0, respectively (both p < 0.001). The general quality-of-life index increased significantly from 6 to 9 (p < 0.001). Forty-two (79.2%) patients judged the result as very satisfactory and would highly recommend uterine fibroid embolization to other patients.
Uterine fibroid embolization leads to an impressive mid- and long-term improvement of all investigated physical and psychological fibroid-related and fibroid-associated symptoms and significantly improves women's health-related quality of life.
我们的目的是评估接受子宫肌瘤栓塞治疗的患者在肌瘤特异性和肌瘤相关生活质量方面的中长期结局。
进行了一项回顾性队列研究，纳入连续的患者，其最短随访时间为1年。通过一份由49个问题组成的问卷进行分析，这些问题涉及六个主题：基线特征、干预前状态、诊断检查和治疗计划、围手术期及与手术相关的生活质量、随访以及总体满意度。
基于62例患者中53例（85.5%）的问卷进行分析。平均随访时间为3.0±1.0（标准差）年（范围为1.0 - 5.0年）。子宫肌瘤栓塞使79.2%的患者出血症状减轻（子宫肌瘤栓塞前n = 48例；子宫肌瘤栓塞后n = 10例），81.5%的患者疼痛减轻（分别为n = 27例；n = 5例），78.6%的患者与肿块相关的症状减轻（分别为n = 14例；n = 3例），60%的患者排尿功能障碍减轻（分别为n = 10例；n = 4例），71.4%的患者性功能障碍减轻（分别为n = 7例；n = 2例），62.5%的患者疲劳减轻（分别为n = 24例；n = 9例），88.2%的患者社交生活受限情况改善（分别为n = 17例；n = 2例），89.5%的患者情绪低落情况改善（分别为n = 19例；n = 2例）。出血和疼痛的中位损伤评分分别从6显著降至0和从4显著降至0（均p < 0.001）。总体生活质量指数从6显著提高到9（p < 0.001）。42例（79.2%）患者认为结果非常满意，并会向其他患者强烈推荐子宫肌瘤栓塞术。
子宫肌瘤栓塞术可使所有调查的与肌瘤相关及肌瘤伴发的身体和心理症状在中长期得到显著改善，并显著提高女性的健康相关生活质量。
